EDUCATION
1971-1972 Fellowship,
Endocrinology
University
of
1968-1971 Internship
and Residency, Internal Medicine
University
of
1968 Doctor
of Medicine
1964 Bachelor
of Arts
PROFESSIONAL
EXPERIENCE
May 2010 to Present Senior Medical Director &
Head, Medical Safety Operations
i3
Drug Safety
Basking
§
Provides safety management and medical oversight of
pharmacovigilance activities.
§
Works closely with pharmacovigilance colleagues to ensure
appropriate medical interpretation and consistency are applied to adverse event
case assessment.
§
Ensures compliance with respect to evaluation, reporting and
surveillance of clinical safety information.
§
Identifies, communicates and effectively manages potential
safety issues.
§
Provides investigator support regarding safety concerns,
medical emergencies, etc.
PROFESSIONAL EXPERIENCE, CONTINUED
§
Medical safety surveillance/signal detection for
investigational products and marketed products
§
Discusses and resolves medical issues with clinical sites,
Sponsors, and drug safety staff.
§
Medical review and interpretation for periodic and other
safety reports (e.g., annual safety reports, PSURs, NDA clinical summary of
safety).
§
Signal detection, benefit/risk assessment, and development
of trend analyses.
§
Consults with internal and external customers in areas of
drug safety, pharmacovigilance, and clinical research.
§
Supports business development through participation in core
proposal team activities, feasibility assessments and review of
proposals/contracts for medical services.
§
Line management of i3 Drug Safety physicians.
2008
to 2010 Executive
Medical Director for the
Medical
& Scientific Affairs, i3 Research
Basking
§
Provided medical and safety management of clinical trials as
medical monitor for assigned programs; works closely with safety associates in
evaluation, management, and assessment of adverse event reports.
§
Assisted the Global Vice President in day-to-day management
of medical and safety staff, as assigned.
§
Maintained
a working knowledge of projects in his/her functional area for which i3
Research is responsible for medical and/or safety monitoring.
§
Supported
Business Development through participation in core proposal team activities, feasibility
assessments, review of proposals/contracts for medical services, and attendance
at meetings with sponsors, as requested.
PROFESSIONAL
EXPERIENCE, CONTINUED
§
Stayed
abreast of clinical and drug development information relevant to contracted
programs by review of literature, attendance at medical/scientific meetings,
and personal interchanges with consultants and investigators.
§
Provided
a medical perspective to the design of clinical development programs and study
protocols; provide expert input into the development, review, and editing of
clinical documents.
§
Collaborated
with sponsors and/or internal departments on the design and review of
study-related documents and professional manuscripts.
§
Assisted
the Global Vice President as appropriate by serving as a mentor and
role model for other medical and safety staff.
§
Assisted
the Global Vice President as required in identifying training needs
and coordinate the implementation of training programs for medical and safety
staff.
§
Independently,
and in collaboration with Business-development staff, pursued novel business
opportunities to enhance corporate revenue.
§
Interacted
with other functional units, such as project management, field monitoring, data
management and statistics, et al. to ensure the highest level of client
satisfaction through successful execution and completion of projects.
§
Maintained
a high level of expertise with client projects and marketplace developments
through reliable participation in internal meetings, including project
tracking, and attendance at professional seminars and educational programs.
§
Provided
protocol-related clinical and scientific training to project team staff
members.
§
Participated
in medical/scientific education for i3 Research staff through scheduled
lectures and seminars on subjects relevant to company projects and on areas of
individual interest and expertise.
§
Performed
any other duties that may, from time to time, be assigned by the Vice
President, Medical & Scientific Affairs.
PROFESSIONAL
EXPERIENCE, CONTINUED
2007
to 2008 Senior Medical Director, Endocrinology & Metabolic
Disease
Medical
& Scientific Affairs, i3 Research
Basking
2005
to 2007 Director,
Global Pharmacovigilance and Head, Case Review Physicians Group - Global
Pharmacovigilance
Schering-Plough
Research Institute
§
Managed
a group of 13 safety physicians who reviewed single cases.
§
Reviewed
and revised SOPs and pharmacovigilance process guides.
§
Served
as leader of special project to transition review of clinical trial SAEs to
GPV.
§
Served
as co-chair of team to develop case handling conventions.
§
Coordinated
medical review activities in implementation of new pharmacovigilance database
(August 2006).
§
Participated
in other management activities within GPV.
2001
to 2005 Associate
Director, Global Pharmacovigilance and Epidemiology
Sanofi-Aventis
(formerly Aventis Pharmaceuticals)
§
Primary
responsibility for clinical safety and post-marketing surveillance of diabetes
and other products.
§
Reviewed
single cases of adverse events, participated in preparation of PSURs, periodic
reports, CTDs, risk management plans; reviewed issues and wrote reports (e.g.,
for labeling committee); reviewed draft publications.
§
Participated
as pharmacovigilance member of clinical teams (including multiple
joint-development projects).
PROFESSIONAL
EXPERIENCE, CONTINUED
1998 to 2001 Associate Medical
Director, Drug Safety Surveillance
Pfizer
Inc. (formerly Parke-Davis Pharmaceutical Research)
§
Primary
responsibility for post-marketing safety of diabetes products.
§
Reviewed
single cases of adverse events, participated in preparation of PSURs and
periodic reports, interacted with consultants, reviewed issues and wrote
reports, supervised other physicians.
1997
to 1998 Medical
Staff (part-time)
§
Reviewed
medical records of registrants, participated in interviews of registrants,
advised board on medical issues surrounding registrants.
1986-1998 Private Practice
Physician (Endocrinology)
Kansas
City/Independence, MO,
1985-1986 Private Practice
Physician (Endocrinology)
Midwest
Diabetes and
1981-1985 Private Practice
Physician (Endocrinology)
Downtown
Yankton Medical Clinic
1978-1985 Director of
Medical Services (part-time)
§
Supervised
physician assistants, laboratory services, substance abuse program, and nursing
home unit.
PROFESSIONAL
EXPERIENCE, CONTINUED
§
Provided
internal medicine consultations.
§
Served
as member of senior staff.
1978-1985 Associate
Professor of Internal Medicine and Psychiatry (part-time)
University
of
§
Participated
in third-year student internal medicine rotations, fourth-year student
endocrinology, and other elective rotations.
§
Supervised
students on psychiatry rotations at SDHSC.
§
Participated
as full (not clinical) faculty in internal medicine and psychiatry departments.
1974-1981 Private Practice
Physician (Internal Medicine)
Yankton
Medical Clinic (formerly Yankton Clinic, PA)
1972-1974 Deputy
Chief of Medicine, Department of Internal Medicine
LICENSURE/CERTIFICATION
1986 to Present Medical
License
State
of
(Previous
medical licenses in
1994 Fellow
1986,
1992, 1997 Certified
Diabetes Educator
National
Certification Board for Diabetes Educators
1977 Fellow
LICENSURE/CERTIFICATION,
CONTINUED
1977 Certification
Subspecialty Board on Endocrinology,
Diabetes and Metabolism
American Board of Internal Medicine
1974 Certification
American
Board of Internal Medicine
PROFESSIONAL INTERESTS
Diabetes
Education and Diabetes Care
§
American
Association of Diabetes Educators
Board of Directors, 1979 – 1987
Treasurer
Vice President
President-Elect
President, 1985 – 1986
§
American
Diabetes Association
President, SD Affiliate, 1974 – 1975
Missouri Affiliate, 1986 – 1998
Kansas City Chapter of MO Affiliate: Board of Directors, 1987 – 1994
Served on several state committees of MO Affiliate, 1987 – 1997
Representative to Central Council of ADA, 1985 – 1991
Eastern Jackson County Chapter of MO Affiliate: Board of Directors, 1995 – 1997
§
Medical
Director, Midwest Diabetes Care Center, Inc., 1986 – 1998
§
Missouri
Department of Health, Bureau of High Risk Intervention, Diabetes Advisory
Committee, 1990 – 1998
Co-chair, 1991 – 1994
Chair, 1994 – 1998
§
Author, The Other Tests Your Doctor Orders. Diabetes
in the News, August, 1988
§
Reviewer for
articles about diabetes for The Medical Letter® On Drugs and Therapeutics,
1993 – 1998
§
Writer of
articles about diabetes for Diabetes Interview, 1998
§
Writer of
articles about diabetes for Diabetes Digest, 1998
§
President,
Diabetes123 (owner of www.childrenwithdiabetes.com), 2001 – 2002
PROFESSIONAL INTERESTS, CONTINUED
Diabetes
Education and Diabetes Care
§
Member
of Diabetes Care Guidelines Revision Task Force, American Association of Clinical Endocrinologists, 2005 – 2007
§
Writer of blogs
about diabetes for MyDiabetesCentral.com,
2006 – present
Medical
Education
Drug
Safety
Medical
Applications of Computers
Recent
Attendance at Professional Meetings
PROFESSIONAL INTERESTS, CONTINUED
Recent
Attendance at Professional Meetings
PROFESSIONAL
MEMBERSHIPS
1991 to Present American
Association of Clinical Endocrinologists
Charter
Member
1979 to Present American
Association of Diabetes Educators
1994 to Present
1972 to Present
1972 to Present American Diabetes Association
1999 to Present Drug Information Association
2004 to Present Endocrine Society
SUMMARY
OF THERAPEUTIC EXPERIENCE
Pharmacovigilance,
endocrinology, internal medicine, clinical trials.
ABSTRACTS
Quick WW, et al. Reporting Rate of Jaundice/Hyperbilirubinemia
in Troglitazone Treated Patients Has Decreased. American Association of
Clinical Endocrinologists, May 2000,
Quick WW, et al. Reporting Rate of Liver Transplant and Death
with Troglitazone Has Decreased. American Diabetes Association, June 2000,
Huang EA, Zdon GS, Moore RJ,
Moran HJ, Reidel V, Quick WW. Trends in early metformin monotherapy for newly
diagnosed type 2 diabetes in the United States, 2001-2007. American Diabetes
Association, June 2009,
PUBLICATIONS
Quick WW. Diagnosis of
diabetes: use of the oral glucose tolerance test. Mo Med. 1972 Apr;69(4):275-7
Quick WW. Filing and
retrieving medical literature. JAMA. 1979 Aug 24-31;242(8):710-1.
Quick
WW. Pathophysiology of Diabetes. In Diabetes Education: A Core Curriculum for
Health Professionals, American Association of Diabetes Educators, 1988; Second
Edition, 1993
Zhang Y, Dall TM, Mann SE, Chen Y, Martin J,
Dall TM, Mann SE, Zhang Y, Quick WW, Seifert RF, Martin, J,
Huang EA, Zhang, S. Distinguishing the Economic Costs Associated with Type 1
and Type 2 Diabetes. Population Health Management. 2009, 12(2): 103-110.
Zhang Y, Dall TM, Chen Y, Baldwin A, Yang W, Mann SE,
Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, Moran J,
Huang EA, Zdon GS, Moore RJ, Moran HJ, Quick WW. The impact of publishing
medical specialty society guidelines on subsequent adoption of best practices:
a case study with type 2 diabetes. Int J Clin Pract. Accepted for publication
December 2009.
Dall TM, Zhang Y, Chen
YJ, Quick WW, Yang WG, Fogli J. The Economic Burden Of Diabetes.
Health Affairs. 2010, 29(2): 1-7.
AUTHENTICATION
The
information contained in this document is accurate and complete to the best of
my knowledge.
Employee/Contractor ID Number ___000541296________
_
Signature Date